Skip to main content

Table 5 Biochemical characteristics of the patients according to thrombosis and bleeding status

From: Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

 

Thrombosis

Bleeding

No

Yes

No

Yes

ALC (peak), × 109/L

14.20

15.00

13.18

14.20

(3.80‒52.00)

(1.90‒40.24)

(3.70–50.60)

(1.50–40.24)

Albumin (nadir), g/dL

3.20

3.10

3.20

3.05

(2.80‒3.80)

(2.70‒3.60)

(2.80–3.80)

(2.82–3.50)

CRP, mg/L

21.76

25.00

22.75

23.40

(peak) (× times the ULN)

(11.40‒36.80)

(14.80‒41.73)

(11.80–37.20)

(9.91–35.48)

CAR

7.01

8.26

7.23

7.45

(3.55‒11.83)

(5.15‒16.72)

(3.70–12.39)

(4.20–15.61)

D-dimer, mg/L

2.82

9.76

2.88

6.11

(peak) (× times the ULN)

(1.65‒6.53)

(3.36‒33.20)*

(1.64–7.44)

(3.12–31.76)*

  1. Data are presented as median with 25–75th percentile; *p < 0.05
  2. ALC absolute lymphocyte count, IQR interquartile range, CRP C-reactive protein, CAR C-reactive protein to albumin ratio, ULN upper limit of normal